nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.148	0.282	CbGbCtD
Avanafil—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0998	0.19	CbGbCtD
Avanafil—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0952	0.182	CbGbCtD
Avanafil—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0849	0.162	CbGbCtD
Avanafil—PDE5A—pulmonary artery—chronic obstructive pulmonary disease	0.0536	0.649	CbGeAlD
Avanafil—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0498	0.0949	CbGbCtD
Avanafil—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.047	0.0897	CbGbCtD
Avanafil—PDE5A—respiratory system—chronic obstructive pulmonary disease	0.00902	0.109	CbGeAlD
Avanafil—PDE5A—connective tissue—chronic obstructive pulmonary disease	0.00794	0.0961	CbGeAlD
Avanafil—PDE5A—smooth muscle tissue—chronic obstructive pulmonary disease	0.00727	0.0879	CbGeAlD
Avanafil—PDE5A—lung—chronic obstructive pulmonary disease	0.00479	0.058	CbGeAlD
Avanafil—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00196	0.102	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00174	0.0905	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—chronic obstructive pulmonary disease	0.00168	0.0878	CbGpPWpGaD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00142	0.074	CbGpPWpGaD
Avanafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS3—chronic obstructive pulmonary disease	0.00135	0.0706	CbGpPWpGaD
Avanafil—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00274	CcSEcCtD
Avanafil—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00274	CcSEcCtD
Avanafil—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00273	CcSEcCtD
Avanafil—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00273	CcSEcCtD
Avanafil—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00101	0.0027	CcSEcCtD
Avanafil—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.001	0.00269	CcSEcCtD
Avanafil—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.001	0.00268	CcSEcCtD
Avanafil—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000998	0.00267	CcSEcCtD
Avanafil—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000994	0.00266	CcSEcCtD
Avanafil—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000981	0.00263	CcSEcCtD
Avanafil—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000972	0.0026	CcSEcCtD
Avanafil—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000971	0.0026	CcSEcCtD
Avanafil—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000967	0.00259	CcSEcCtD
Avanafil—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000967	0.00259	CcSEcCtD
Avanafil—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000967	0.00259	CcSEcCtD
Avanafil—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000967	0.00259	CcSEcCtD
Avanafil—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000965	0.00258	CcSEcCtD
Avanafil—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000965	0.00258	CcSEcCtD
Avanafil—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000957	0.00256	CcSEcCtD
Avanafil—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000957	0.00256	CcSEcCtD
Avanafil—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000957	0.00256	CcSEcCtD
Avanafil—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000954	0.00255	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000951	0.00254	CcSEcCtD
Avanafil—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00095	0.00254	CcSEcCtD
Avanafil—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000948	0.00254	CcSEcCtD
Avanafil—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000942	0.00252	CcSEcCtD
Avanafil—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000942	0.00252	CcSEcCtD
Avanafil—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000939	0.00251	CcSEcCtD
Avanafil—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000939	0.00251	CcSEcCtD
Avanafil—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.000938	0.00251	CcSEcCtD
Avanafil—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000936	0.00251	CcSEcCtD
Avanafil—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000928	0.00248	CcSEcCtD
Avanafil—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000922	0.00247	CcSEcCtD
Avanafil—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00092	0.00246	CcSEcCtD
Avanafil—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00092	0.00246	CcSEcCtD
Avanafil—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000919	0.00246	CcSEcCtD
Avanafil—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000914	0.00245	CcSEcCtD
Avanafil—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000913	0.00244	CcSEcCtD
Avanafil—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000913	0.00244	CcSEcCtD
Avanafil—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000913	0.00244	CcSEcCtD
Avanafil—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000913	0.00244	CcSEcCtD
Avanafil—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000912	0.00244	CcSEcCtD
Avanafil—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000909	0.00243	CcSEcCtD
Avanafil—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000907	0.00243	CcSEcCtD
Avanafil—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000907	0.00243	CcSEcCtD
Avanafil—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.0009	0.00241	CcSEcCtD
Avanafil—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000896	0.0024	CcSEcCtD
Avanafil—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000894	0.00239	CcSEcCtD
Avanafil—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000893	0.00239	CcSEcCtD
Avanafil—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000891	0.00239	CcSEcCtD
Avanafil—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000889	0.00238	CcSEcCtD
Avanafil—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000887	0.00237	CcSEcCtD
Avanafil—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00088	0.00236	CcSEcCtD
Avanafil—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000878	0.00235	CcSEcCtD
Avanafil—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000878	0.00235	CcSEcCtD
Avanafil—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000872	0.00233	CcSEcCtD
Avanafil—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000872	0.00233	CcSEcCtD
Avanafil—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000867	0.00232	CcSEcCtD
Avanafil—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000862	0.00231	CcSEcCtD
Avanafil—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000857	0.00229	CcSEcCtD
Avanafil—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000857	0.00229	CcSEcCtD
Avanafil—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000855	0.00229	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000836	0.00224	CcSEcCtD
Avanafil—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000834	0.00223	CcSEcCtD
Avanafil—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000834	0.00223	CcSEcCtD
Avanafil—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00083	0.00222	CcSEcCtD
Avanafil—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000829	0.00222	CcSEcCtD
Avanafil—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000824	0.0022	CcSEcCtD
Avanafil—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000817	0.00219	CcSEcCtD
Avanafil—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000808	0.00216	CcSEcCtD
Avanafil—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000802	0.00215	CcSEcCtD
Avanafil—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000802	0.00215	CcSEcCtD
Avanafil—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000792	0.00212	CcSEcCtD
Avanafil—Cough—Formoterol—chronic obstructive pulmonary disease	0.000792	0.00212	CcSEcCtD
Avanafil—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000792	0.00212	CcSEcCtD
Avanafil—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000787	0.00211	CcSEcCtD
Avanafil—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000785	0.0021	CcSEcCtD
Avanafil—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000785	0.0021	CcSEcCtD
Avanafil—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000783	0.0021	CcSEcCtD
Avanafil—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000783	0.0021	CcSEcCtD
Avanafil—Cough—Montelukast—chronic obstructive pulmonary disease	0.000776	0.00208	CcSEcCtD
Avanafil—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000773	0.00207	CcSEcCtD
Avanafil—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00077	0.00206	CcSEcCtD
Avanafil—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000769	0.00206	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000767	0.00205	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000767	0.00205	CcSEcCtD
Avanafil—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000757	0.00203	CcSEcCtD
Avanafil—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000757	0.00203	CcSEcCtD
Avanafil—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000757	0.00203	CcSEcCtD
Avanafil—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000756	0.00202	CcSEcCtD
Avanafil—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000756	0.00202	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000751	0.00201	CcSEcCtD
Avanafil—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000748	0.002	CcSEcCtD
Avanafil—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00074	0.00198	CcSEcCtD
Avanafil—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000736	0.00197	CcSEcCtD
Avanafil—Infection—Formoterol—chronic obstructive pulmonary disease	0.000736	0.00197	CcSEcCtD
Avanafil—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000729	0.00195	CcSEcCtD
Avanafil—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000729	0.00195	CcSEcCtD
Avanafil—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000729	0.00195	CcSEcCtD
Avanafil—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000726	0.00194	CcSEcCtD
Avanafil—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000726	0.00194	CcSEcCtD
Avanafil—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000723	0.00193	CcSEcCtD
Avanafil—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000723	0.00193	CcSEcCtD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000721	0.0376	CbGpPWpGaD
Avanafil—Infection—Montelukast—chronic obstructive pulmonary disease	0.000721	0.00193	CcSEcCtD
Avanafil—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000719	0.00193	CcSEcCtD
Avanafil—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000719	0.00193	CcSEcCtD
Avanafil—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000713	0.00191	CcSEcCtD
Avanafil—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000711	0.0019	CcSEcCtD
Avanafil—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000705	0.00189	CcSEcCtD
Avanafil—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000695	0.00186	CcSEcCtD
Avanafil—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000692	0.00185	CcSEcCtD
Avanafil—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000692	0.00185	CcSEcCtD
Avanafil—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000688	0.00184	CcSEcCtD
Avanafil—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000686	0.00184	CcSEcCtD
Avanafil—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000682	0.00183	CcSEcCtD
Avanafil—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000682	0.00182	CcSEcCtD
Avanafil—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000679	0.00182	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000675	0.00181	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000675	0.00181	CcSEcCtD
Avanafil—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00067	0.00179	CcSEcCtD
Avanafil—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00067	0.00179	CcSEcCtD
Avanafil—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000666	0.00178	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000661	0.00177	CcSEcCtD
Avanafil—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000658	0.00176	CcSEcCtD
Avanafil—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000658	0.00176	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—NOS2—chronic obstructive pulmonary disease	0.000656	0.0342	CbGpPWpGaD
Avanafil—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000656	0.00176	CcSEcCtD
Avanafil—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000653	0.00175	CcSEcCtD
Avanafil—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000652	0.00174	CcSEcCtD
Avanafil—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000652	0.00174	CcSEcCtD
Avanafil—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000649	0.00174	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000648	0.0338	CbGpPWpGaD
Avanafil—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000645	0.00173	CcSEcCtD
Avanafil—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000643	0.00172	CcSEcCtD
Avanafil—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000642	0.00172	CcSEcCtD
Avanafil—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000639	0.00171	CcSEcCtD
Avanafil—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000639	0.00171	CcSEcCtD
Avanafil—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000639	0.00171	CcSEcCtD
Avanafil—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000638	0.00171	CcSEcCtD
Avanafil—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000638	0.00171	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000637	0.00171	CcSEcCtD
Avanafil—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000633	0.00169	CcSEcCtD
Avanafil—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000633	0.00169	CcSEcCtD
Avanafil—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000632	0.00169	CcSEcCtD
Avanafil—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000626	0.00168	CcSEcCtD
Avanafil—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000625	0.00167	CcSEcCtD
Avanafil—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000622	0.00166	CcSEcCtD
Avanafil—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000619	0.00166	CcSEcCtD
Avanafil—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000616	0.00165	CcSEcCtD
Avanafil—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000614	0.00164	CcSEcCtD
Avanafil—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000613	0.00164	CcSEcCtD
Avanafil—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00061	0.00163	CcSEcCtD
Avanafil—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000607	0.00162	CcSEcCtD
Avanafil—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000604	0.00162	CcSEcCtD
Avanafil—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000603	0.00161	CcSEcCtD
Avanafil—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000598	0.0016	CcSEcCtD
Avanafil—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000585	0.00157	CcSEcCtD
Avanafil—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000585	0.00157	CcSEcCtD
Avanafil—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000583	0.00156	CcSEcCtD
Avanafil—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000579	0.00155	CcSEcCtD
Avanafil—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000578	0.00155	CcSEcCtD
Avanafil—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000578	0.00155	CcSEcCtD
Avanafil—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000575	0.00154	CcSEcCtD
Avanafil—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000573	0.00153	CcSEcCtD
Avanafil—PDE5A—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000566	0.0295	CbGpPWpGaD
Avanafil—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000553	0.00148	CcSEcCtD
Avanafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000552	0.0288	CbGpPWpGaD
Avanafil—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000545	0.00146	CcSEcCtD
Avanafil—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000531	0.00142	CcSEcCtD
Avanafil—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000531	0.00142	CcSEcCtD
Avanafil—PDE5A—Platelet homeostasis—NOS3—chronic obstructive pulmonary disease	0.000527	0.0275	CbGpPWpGaD
Avanafil—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000524	0.0014	CcSEcCtD
Avanafil—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000524	0.0014	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000523	0.0014	CcSEcCtD
Avanafil—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00052	0.00139	CcSEcCtD
Avanafil—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000513	0.00137	CcSEcCtD
Avanafil—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000507	0.00136	CcSEcCtD
Avanafil—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000507	0.00136	CcSEcCtD
Avanafil—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000502	0.00134	CcSEcCtD
Avanafil—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000496	0.00133	CcSEcCtD
Avanafil—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000495	0.00132	CcSEcCtD
Avanafil—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00049	0.00131	CcSEcCtD
Avanafil—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00049	0.00131	CcSEcCtD
Avanafil—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00048	0.00128	CcSEcCtD
Avanafil—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000478	0.00128	CcSEcCtD
Avanafil—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000471	0.00126	CcSEcCtD
Avanafil—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000471	0.00126	CcSEcCtD
Avanafil—Rash—Formoterol—chronic obstructive pulmonary disease	0.000467	0.00125	CcSEcCtD
Avanafil—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000467	0.00125	CcSEcCtD
Avanafil—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000467	0.00125	CcSEcCtD
Avanafil—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000467	0.00125	CcSEcCtD
Avanafil—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000466	0.00125	CcSEcCtD
Avanafil—Headache—Formoterol—chronic obstructive pulmonary disease	0.000464	0.00124	CcSEcCtD
Avanafil—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000464	0.00124	CcSEcCtD
Avanafil—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000463	0.00124	CcSEcCtD
Avanafil—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000462	0.00124	CcSEcCtD
Avanafil—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000461	0.00123	CcSEcCtD
Avanafil—Rash—Montelukast—chronic obstructive pulmonary disease	0.000457	0.00122	CcSEcCtD
Avanafil—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000457	0.00122	CcSEcCtD
Avanafil—Headache—Montelukast—chronic obstructive pulmonary disease	0.000454	0.00122	CcSEcCtD
Avanafil—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.00119	CcSEcCtD
Avanafil—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000442	0.00118	CcSEcCtD
Avanafil—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000441	0.00118	CcSEcCtD
Avanafil—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00044	0.00118	CcSEcCtD
Avanafil—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00044	0.00118	CcSEcCtD
Avanafil—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00044	0.00118	CcSEcCtD
Avanafil—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000438	0.00117	CcSEcCtD
Avanafil—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000431	0.00115	CcSEcCtD
Avanafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000428	0.0223	CbGpPWpGaD
Avanafil—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000424	0.00114	CcSEcCtD
Avanafil—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000415	0.00111	CcSEcCtD
Avanafil—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000403	0.00108	CcSEcCtD
Avanafil—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000391	0.00105	CcSEcCtD
Avanafil—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000383	0.00103	CcSEcCtD
Avanafil—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000381	0.00102	CcSEcCtD
Avanafil—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000372	0.000996	CcSEcCtD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000372	0.0194	CbGpPWpGaD
Avanafil—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000371	0.000992	CcSEcCtD
Avanafil—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000363	0.000971	CcSEcCtD
Avanafil—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000359	0.000962	CcSEcCtD
Avanafil—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000357	0.000956	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000339	0.0176	CbGpPWpGaD
Avanafil—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000337	0.000901	CcSEcCtD
Avanafil—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000328	0.000878	CcSEcCtD
Avanafil—PDE5A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000325	0.017	CbGpPWpGaD
Avanafil—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000324	0.0169	CbGpPWpGaD
Avanafil—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000321	0.000859	CcSEcCtD
Avanafil—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000311	0.0162	CbGpPWpGaD
Avanafil—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000825	CcSEcCtD
Avanafil—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000304	0.000814	CcSEcCtD
Avanafil—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000304	0.000814	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000302	0.000808	CcSEcCtD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000299	0.0156	CbGpPWpGaD
Avanafil—Infection—Prednisone—chronic obstructive pulmonary disease	0.00029	0.000775	CcSEcCtD
Avanafil—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000765	CcSEcCtD
Avanafil—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000284	0.000761	CcSEcCtD
Avanafil—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000283	0.000758	CcSEcCtD
Avanafil—PDE5A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000282	0.0147	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00027	0.0141	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000711	CcSEcCtD
Avanafil—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000265	0.00071	CcSEcCtD
Avanafil—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000264	0.000706	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000259	0.0135	CbGpPWpGaD
Avanafil—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000257	0.000687	CcSEcCtD
Avanafil—PDE5A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000253	0.0132	CbGpPWpGaD
Avanafil—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.000677	CcSEcCtD
Avanafil—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.000676	CcSEcCtD
Avanafil—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000673	CcSEcCtD
Avanafil—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.000672	CcSEcCtD
Avanafil—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000249	0.000667	CcSEcCtD
Avanafil—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000246	0.0128	CbGpPWpGaD
Avanafil—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000238	0.000638	CcSEcCtD
Avanafil—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.00023	0.000617	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000228	0.0119	CbGpPWpGaD
Avanafil—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000226	0.0118	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000217	0.0113	CbGpPWpGaD
Avanafil—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000209	0.00056	CcSEcCtD
Avanafil—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000206	0.000552	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000204	0.0106	CbGpPWpGaD
Avanafil—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000199	0.000534	CcSEcCtD
Avanafil—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000193	0.000516	CcSEcCtD
Avanafil—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000496	CcSEcCtD
Avanafil—Rash—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000492	CcSEcCtD
Avanafil—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000491	CcSEcCtD
Avanafil—Headache—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000489	CcSEcCtD
Avanafil—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000463	CcSEcCtD
Avanafil—PDE5A—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000163	0.0085	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.00016	0.00834	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00016	0.00833	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000147	0.00766	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000132	0.00689	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000129	0.00673	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.00665	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000124	0.00645	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000124	0.00644	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000118	0.00616	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000116	0.00605	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000105	0.00546	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.39e-05	0.00489	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.27e-05	0.00483	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	8.51e-05	0.00444	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	7.81e-05	0.00407	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.61e-05	0.00397	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.7e-05	0.00349	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.62e-05	0.00345	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—TP53—chronic obstructive pulmonary disease	6.43e-05	0.00335	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.56e-05	0.0029	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.49e-05	0.00286	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.64e-05	0.00242	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.58e-05	0.00239	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.26e-05	0.00222	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.21e-05	0.00219	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.04e-05	0.00211	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.99e-05	0.00208	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.25e-05	0.0017	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.15e-05	0.00112	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.1e-05	0.00109	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.95e-05	0.00102	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.15e-05	0.000597	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.13e-05	0.00059	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.03e-05	0.000538	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.52e-06	0.000496	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.94e-06	0.000414	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.83e-06	0.000408	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.29e-06	0.00038	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.91e-06	0.00036	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.7e-06	0.000245	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	4.5e-06	0.000234	CbGpPWpGaD
